Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Actinium Pharmaceuticals Inc.
DescriptionActinium-225 attached to the anti-CD33 mAb lintuzumab (HuM195)
Molecular Target CD33
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML); Treat acute myelogenous leukemia (AML) in newly diagnosed patients
Regulatory Designation U.S. - Orphan Drug (Treat acute myelogenous leukemia (AML))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today